2021
Bloodstream Infections in Children With Sickle Cell Disease: 2010-2019.
Yee ME, Lai KW, Bakshi N, Grossman JK, Jaggi P, Mallis A, Wang YF, Jerris RC, Lane PA, Yildirim I. Bloodstream Infections in Children With Sickle Cell Disease: 2010-2019. Pediatrics 2021, 149 PMID: 34913059, PMCID: PMC8959248, DOI: 10.1542/peds.2021-051892.Peer-Reviewed Original ResearchConceptsSickle cell diseaseBloodstream infectionsBlood culturesSickle cell anemia genotypesRetrospective cohort studyInvasive bacterial infectionsMultivariate logistic regressionConfidence intervalsAverage incidence rateSpectrum of pathogensAntibiotic prophylaxisEligible patientsFunctional aspleniaBSI episodesCohort studyChronic transfusionMedian ageAnnual incidenceOverall incidenceRisk factorsIncidence rateCell diseaseEmpirical treatmentBordetella holmesiiCommon pathogensA Retrospective Test-Negative Case-Control Study to Evaluate Influenza Vaccine Effectiveness in Preventing Hospitalizations in Children
Yildirim I, Kao CM, Tippett A, Suntarattiwong P, Munye M, Yi J, Elmontser M, Quincer E, Focht C, Watson N, Bilen H, Baker JM, Lopman B, Hogenesch E, Rostad CA, Anderson EJ. A Retrospective Test-Negative Case-Control Study to Evaluate Influenza Vaccine Effectiveness in Preventing Hospitalizations in Children. Clinical Infectious Diseases 2021, 73: 1759-1767. PMID: 34410341, PMCID: PMC8599178, DOI: 10.1093/cid/ciab709.Peer-Reviewed Original ResearchConceptsInfluenza vaccine effectivenessInfluenza-positive casesInfluenza-related hospitalizationsVaccine effectivenessInfluenza seasonOdds ratioInfluenza ALaboratory-confirmed influenza-related hospitalizationsTest-negative case-control study designAdjusted vaccine effectivenessInfluenza-negative controlsTest-negative controlsCase-control study designHospitalization of childrenTest-negative casesConfidence intervalsNon-Hispanic blacksLogistic regression modelsPreventing HospitalizationInfluenza vaccinationInfluenza burdenMedian ageInfluenza B.Influenza infectionPediatric hospitalizationsSafety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
Arrieta AC, Neely M, Day JC, Rheingold SR, Sue PK, Muller WJ, Danziger-Isakov LA, Chu J, Yildirim I, McComsey GA, Frangoul HA, Chen TK, Statler VA, Steinbach WJ, Yin DE, Hamed K, Jones ME, Lademacher C, Desai A, Micklus K, Phillips DL, Kovanda LL, Walsh TJ. Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients. Antimicrobial Agents And Chemotherapy 2021, 65: 10.1128/aac.00290-21. PMID: 34031051, PMCID: PMC8284446, DOI: 10.1128/aac.00290-21.Peer-Reviewed Original ResearchConceptsPhase 1 studyPediatric patientsIsavuconazonium sulfatePlasma drug exposureDrug exposureOral administrationImmunocompromised Pediatric PatientsNew triazole agentProdrug isavuconazonium sulfateTolerability of isavuconazoleBody mass indexPopulation PK modelInvasive fungal infectionsProbability of targetTarget rangeConcentration-time curveFirst-order inputMass indexPopulation pharmacokineticsStepwise covariate modelingTriazole agentsClinical dosePK parametersLinear eliminationPatientsClinical Epidemiology and Outcomes of Pediatric Musculoskeletal Infections
Yi J, Wood JB, Creech CB, Williams D, Jimenez-Truque N, Yildirim I, Sederdahl B, Daugherty M, Hussaini L, Munye M, Tomashek KM, Focht C, Watson N, Anderson EJ, Thomsen I. Clinical Epidemiology and Outcomes of Pediatric Musculoskeletal Infections. The Journal Of Pediatrics 2021, 234: 236-244.e2. PMID: 33771580, PMCID: PMC8238832, DOI: 10.1016/j.jpeds.2021.03.028.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdministration, OralAdolescentAnti-Bacterial AgentsArthritis, InfectiousChildChild, PreschoolCombined Modality TherapyFemaleGram-Negative Bacterial InfectionsGram-Positive Bacterial InfectionsHumansInfantLogistic ModelsMaleMethicillin-Resistant Staphylococcus aureusOrthopedic ProceduresOsteomyelitisRetrospective StudiesStaphylococcal InfectionsTreatment OutcomeUnited StatesConceptsOsteomyelitis/septic arthritisAcute hematogenous osteomyelitisMethicillin-resistant S aureusSeptic arthritisHematogenous osteomyelitisTreatment failureS aureusOral therapyAntibiotic therapyMusculoskeletal infectionsHigher oddsPediatric musculoskeletal infectionsLonger hospital stayOral antibiotic therapyRetrospective cohort studyTreatment-related complicationsTreatment-associated complicationsHospital stayPediatric infectionsCohort studyParenteral therapyTreatment complicationsIntensive careRecurrent infectionsWorse outcomes
2020
Vaccine‐induced protection against hepatitis B in pediatric solid organ transplant patients
Ball M, Liverman R, Serluco A, Yildirim I. Vaccine‐induced protection against hepatitis B in pediatric solid organ transplant patients. Pediatric Transplantation 2020, 25: e13920. PMID: 33217081, DOI: 10.1111/petr.13920.Peer-Reviewed Original ResearchConceptsVaccine-induced protectionPediatric solid organ transplant patientsSolid organ transplant patientsOrgan transplant patientsHepatitis B virusHBV vaccinationTransplant patientsHepatitis B surface antibody titerHBV vaccination coverageHBV vaccine seriesPediatric SOT recipientsDetailed chart reviewYears of ageHBsAb titersSeroprotection ratesSOT recipientsHBV infectionTransplanted childrenVaccine seriesChart reviewHepatitis BLaboratory featuresImmunogenicity dataVaccination coverageVaccine immunityThe burden of respiratory syncytial virus infections among children with sickle cell disease
Rostad CA, Maillis AN, Lai K, Bakshi N, Jerris RC, Lane PA, Yee ME, Yildirim I. The burden of respiratory syncytial virus infections among children with sickle cell disease. Pediatric Blood & Cancer 2020, 68: e28759. PMID: 33034160, PMCID: PMC8246443, DOI: 10.1002/pbc.28759.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusSickle cell diseaseRespiratory viral panelRSV-positive casesRSV infectionAnnual incidenceHospitalization ratesCell diseaseBurden of RSVPediatric lower respiratory tract infectionsLaboratory-confirmed RSV infectionRespiratory syncytial virus infectionRSV-related hospitalization rateLower respiratory tract infectionsRSV positive testRSV-negative childrenRSV-negative patientsAcute chest syndromeSyncytial virus infectionRespiratory tract infectionsAverage annual incidenceMultivariate logistic regressionConfidence intervalsCase-control studyOutcome of childrenMicrobiology and radiographic features of osteomyelitis in children and adolescents with sickle cell disease
Kao CM, Yee ME, Maillis A, Lai K, Bakshi N, Rostad BS, Jerris RC, Lane PA, Yildirim I. Microbiology and radiographic features of osteomyelitis in children and adolescents with sickle cell disease. Pediatric Blood & Cancer 2020, 67: e28517. PMID: 32710705, PMCID: PMC8369475, DOI: 10.1002/pbc.28517.Peer-Reviewed Original ResearchConceptsSickle cell diseaseMethicillin-susceptible Staphylococcus aureusMagnetic resonance imagingAntibiotic treatmentOperative culturesCell diseaseLarge tertiary pediatric centerPrescribed antibiotic treatmentTertiary pediatric centerCulture-positive casesKey presenting symptomsChildren ages 6Bone painMicrobiologic etiologyPresenting symptomPediatric centersBone infarctsMedical chartsMicrobiologic findingsRadiographic featuresImaging featuresOsteomyelitisProbable osteomyelitisDiagnostic codingTissue debridementInitial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed‐release tablet and intravenous posaconazole
Bernardo V, Miles A, Fernandez AJ, Liverman R, Tippett A, Yildirim I. Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed‐release tablet and intravenous posaconazole. Pediatric Transplantation 2020, 24: e13777. PMID: 32639095, DOI: 10.1111/petr.13777.Peer-Reviewed Original ResearchConceptsYears of ageMedian daily doseTrough concentrationsDaily dosePlasma concentrationsYoung adultsPlasma trough concentrationsSerum posaconazole concentrationsInvasive fungal diseaseTherapeutic plasma concentrationsDelayed-release tabletsIntravenous posaconazolePosaconazole dosingImmunocompromised childrenPatients 13Optimal dosingBroad-spectrum antifungalsAdolescent patientsPosaconazole concentrationsHigher dosingPatientsBody weightGrade 1ProphylaxisDosingSevere COVID‐19 disease in two pediatric oncology patients
Stokes CL, Patel PA, Sabnis HS, Mitchell SG, Yildirim IB, Pauly MG. Severe COVID‐19 disease in two pediatric oncology patients. Pediatric Blood & Cancer 2020, 67: e28432. PMID: 32779861, PMCID: PMC7361273, DOI: 10.1002/pbc.28432.Peer-Reviewed Original ResearchBrincidofovir for the treatment of human adenovirus infection in pediatric solid organ transplant recipients: A case series
Londeree J, Winterberg PD, Garro R, George RP, Shin S, Liverman R, Serluco A, Romero R, Yildirim I. Brincidofovir for the treatment of human adenovirus infection in pediatric solid organ transplant recipients: A case series. Pediatric Transplantation 2020, 24: e13769. PMID: 32558134, DOI: 10.1111/petr.13769.Peer-Reviewed Original ResearchConceptsPediatric SOT recipientsSOT recipientsCase seriesSevere diseasePediatric solid organ transplant recipientsSolid organ transplant recipientsType of allograftMainstay of treatmentOrgan transplant recipientsSeverity of diseaseHuman adenovirus infectionHAdV diseaseHAdV viremiaPediatric recipientsTransplant recipientsHAdV infectionDisease courseAntiviral therapySignificant morbidityDisease presentationUS FDAAdenovirus infectionBrincidofovirDiseaseRecipientsInfluenza vaccine effectiveness and disease burden in children and adolescents with sickle cell disease: 2012‐2017
Kao CM, Lai K, McAteer JM, Elmontser M, Quincer EM, Yee MEM, Tippet A, Jerris RC, Lane PA, Anderson EJ, Bakshi N, Yildirim I. Influenza vaccine effectiveness and disease burden in children and adolescents with sickle cell disease: 2012‐2017. Pediatric Blood & Cancer 2020, 67: e28358. PMID: 32469138, PMCID: PMC8221251, DOI: 10.1002/pbc.28358.Peer-Reviewed Original ResearchConceptsInfluenza vaccine effectivenessSickle cell diseaseVaccine effectivenessYears of ageInfluenza infectionOdds ratioCell diseaseLaboratory-confirmed influenza infectionSeasonal influenza vaccine effectivenessTest-negative case-control study designAdjusted vaccine effectivenessAdjusted VE estimatesInfluenza-positive casesOverall vaccine effectivenessAcute chest syndromeBurden of influenzaPatients 6 monthsMulticenter prospective studyTest-negative controlsAnnual influenza vaccineCase-control study designConfidence intervalsLogistic regression modelsChest syndromeInfluenza seasonWho is at risk of 13-valent conjugated pneumococcal vaccine failure?
Yildirim M, Keskinocak P, Pelton S, Pickering L, Yildirim I. Who is at risk of 13-valent conjugated pneumococcal vaccine failure? Vaccine 2020, 38: 1671-1677. PMID: 31974018, DOI: 10.1016/j.vaccine.2019.12.060.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseVaccine failureIPD casesVaccine serotypesDiagnosis of IPDHigh vaccine coverage ratesPneumococcal conjugate vaccineVaccine coverage ratesUnderlying risk factorsYears of ageMonths of agePneumococcal pneumoniaImmunization PracticesVaccine scheduleConjugate vaccinePneumococcal diseasePrimary dosesClinical presentationImmunization scheduleSerotype 19ACourse of immunisationRisk factorsComorbiditiesStudy periodPassive surveillance
2019
Cryptosporidiosis among solid organ transplant recipient attendees at a summer camp
McAteer J, Jernigan S, Mao C, Gonzalez MD, Watson RJ, Liverman R, Angelo M, M. H, Shane A, Yildirim I. Cryptosporidiosis among solid organ transplant recipient attendees at a summer camp. Pediatric Transplantation 2019, 24: e13649. PMID: 31885132, DOI: 10.1111/petr.13649.Peer-Reviewed Original ResearchConceptsTransplant recipientsSolid organ transplant recipientsKidney transplant recipientsRetrospective cohort studyOrgan transplant recipientsPediatric transplant recipientsOverall attack rateAcute rejection eventsLong-term interventionsImmunosuppressive therapySymptom durationCohort studyRisk factorsNotable burdenStool specimensCryptosporidiosis infectionEtiologic agentRejection eventsAttack rateFurther outbreaksInfectionRecipientsCryptosporidium hominisCryptosporidiosisOutbreakSirolimus‐associated pericardial effusion with cardiac tamponade and interstitial pneumonitis in a hematopoietic stem cell transplant recipient
Joo SJ, Yildirim I, Stenger EO, Anderson EJ. Sirolimus‐associated pericardial effusion with cardiac tamponade and interstitial pneumonitis in a hematopoietic stem cell transplant recipient. Pediatric Transplantation 2019, 23: e13425. PMID: 31012209, DOI: 10.1111/petr.13425.Peer-Reviewed Original ResearchConceptsHSCT patientsCardiac tamponadeInterstitial pneumonitisPericardial effusionAllogeneic hematopoietic stem cell transplant patientsHematopoietic stem cell transplant recipientsHematopoietic stem cell transplant patientsStem cell transplant patientsStem cell transplant recipientsAllogeneic HSCT patientsCell transplant recipientsLife-threatening complicationsCell transplant patientsTreatment of graftInvasive fungal infectionsGVHD prophylaxisHost diseaseTransplant patientsTransplant recipientsSirolimus useRapamycin inhibitorsPotent immunosuppressantPatientsFungal infectionsMammalian targetIncidence of invasive Haemophilus influenzae infections in children with sickle cell disease
Yee ME, Bakshi N, Graciaa SH, Lane PA, Jerris RC, Wang YF, Yildirim I. Incidence of invasive Haemophilus influenzae infections in children with sickle cell disease. Pediatric Blood & Cancer 2019, 66: e27642. PMID: 30724001, PMCID: PMC6472970, DOI: 10.1002/pbc.27642.Peer-Reviewed Original ResearchConceptsSickle cell diseaseComprehensive clinical databaseInfluenzae infectionAntibiotic prophylaxisInfluenzae diseaseInvasive infectionsCell diseaseInvasive Haemophilus influenzae infectionsPediatric tertiary care centerHaemophilus influenzae type bLarge pediatric tertiary care centerUniversal antibiotic prophylaxisSterile body fluid culturesTertiary care centerHaemophilus influenzae infectionsBody fluid culturesInfluenzae type bYears of ageDistribution of serotypesNonvaccine serotypesClinical featuresOverall incidenceCare centerFluid cultureIncidence rate
2018
Impact of Pharmacy-Initiated Interventions on Influenza Vaccination Rates in Pediatric Solid Organ Transplant Recipients
Gattis S, Yildirim I, Shane AL, Serluco S, McCracken C, Liverman R. Impact of Pharmacy-Initiated Interventions on Influenza Vaccination Rates in Pediatric Solid Organ Transplant Recipients. Journal Of The Pediatric Infectious Diseases Society 2018, 8: 525-530. PMID: 30307524, DOI: 10.1093/jpids/piy095.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsPediatric SOT recipientsInfluenza vaccination ratesOrgan transplant recipientsSOT recipientsTransplant recipientsInfluenza infectionVaccination ratesVaccination coveragePediatric solid organ transplant recipientsSubsequent graft dysfunctionHeart transplant recipientsInfluenza vaccination coveragePre-post study designNumber of patientsRate of vaccinationGraft dysfunctionInfluenza immunizationInfluenza vaccinationChart reviewPharmacy interventionsMedian timeVaccine coverageTransplant servicesInfluenza rates
2017
Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts’ children to relatively low invasiveness
Yildirim I, Little BA, Finkelstein J, Lee G, Hanage WP, Shea K, Pelton SI, T, Health H. Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts’ children to relatively low invasiveness. Vaccine 2017, 35: 4002-4009. PMID: 28645717, DOI: 10.1016/j.vaccine.2017.05.077.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseasePneumococcal conjugate vaccineInvasive disease potentialPneumococcal diseaseLow invasive capacityInvasive capacityPCV13 eraCommon serotypesIncidence of IPDNasopharyngeal colonization ratePost-vaccine eraDisease potentialCarriage serotypesPCV eraConjugate vaccineNasopharyngeal carriageCarriage prevalencePneumococcal colonizationEnhanced surveillanceDynamic epidemiologyAge groupsSerotype 3Serotype XOlder childrenLow invasiveness
2015
Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine
Yildirim I, Shea KM, Pelton SI. Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine. Infectious Disease Clinics Of North America 2015, 29: 679-697. PMID: 26610421, PMCID: PMC4662776, DOI: 10.1016/j.idc.2015.07.009.Peer-Reviewed Original ResearchConceptsPneumococcal conjugate vaccinePneumococcal diseaseConjugate vaccineOtitis mediaUniversal immunizationAcute otitis mediaInvasive pneumococcal diseaseCase fatality rateVulnerable pediatric patientsSpectrum of serotypesCause pneumoniaPediatric patientsComorbid conditionsHealthy childrenFatality rateDiseaseHost susceptibilityImmunizationVaccineHigh rateChildrenEmpyemaMastoiditisPneumoniaPatients
2012
Evolving Picture of Invasive Pneumococcal Disease in Massachusetts Children
Yildirim I, Stevenson A, Hsu KK, Pelton SI. Evolving Picture of Invasive Pneumococcal Disease in Massachusetts Children. The Pediatric Infectious Disease Journal 2012, 31: 1016-1021. PMID: 22673142, DOI: 10.1097/inf.0b013e3182615615.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnti-Bacterial AgentsChildChild, PreschoolCluster AnalysisFemaleHeptavalent Pneumococcal Conjugate VaccineHumansIncidenceInfantMaleMassachusettsMeningitis, PneumococcalMicrobial Sensitivity TestsMultilocus Sequence TypingPneumococcal VaccinesProspective StudiesSepsisSerotypingStreptococcus pneumoniaeConceptsInvasive pneumococcal diseasePneumococcal conjugate vaccine serotypesPneumococcal conjugate vaccineIPD incidence ratesMassachusetts childrenPCV7 eraIPD casesPneumococcal diseaseConjugate vaccineVaccine serotypesSerotype 19AIncidence rateCases of IPDChildhood invasive pneumococcal diseaseHeptavalent pneumococcal conjugate vaccinePopulation-based surveillanceOverall IPD incidence ratesCeftriaxone-resistant isolatesYears of ageAntimicrobial susceptibility testingBacteremic pneumoniaPCV7 serotypesMultilocus sequence typingNonvaccine serotypesClinical presentation
2010
Serosurveillance study on transmission of H5N1 virus during a 2006 avian influenza epidemic
CEYHAN M, YILDIRIM I, FERRARIS O, BOUSCAMBERT-DUCHAMP M, FROBERT E, UYAR N, TEZER H, ONER AF, BUZGAN T, TORUNOGLU MA, OZKAN B, YILMAZ R, KURTOGLU MG, LALELI Y, BADUR S, LINA B. Serosurveillance study on transmission of H5N1 virus during a 2006 avian influenza epidemic. Epidemiology And Infection 2010, 138: 1274-1280. PMID: 20092669, DOI: 10.1017/s095026880999166x.Peer-Reviewed Original ResearchConceptsSerum samplesSubclinical infectionAvian influenza patientsSingle serum sampleAvian influenzaEnzyme-linked immunoassayPoultry cullersInfluenza patientsMicroneutralization assaysNasopharyngeal swabsPolymerase chain reactionSerosurveillance studiesH5N1 infectionHealthcare workersHaemagglutination inhibitionInfluenza epidemicsHuman infectionsSerological surveyFamily contactsHuman casesH5N1 virusInfectionDiseased poultryInfected chickensChain reaction